Ann Pharmacol Pharm | Volume 6, Issue 1 | Mini Review | Open Access
Sutharson Lingadurai*
Department of Pharmacology, Nirmala College of Health Sciences, India
*Correspondance to: Sutharson Lingadurai
Fulltext PDFCoronavirus Disease - COVID-19 was declared by WHO a pandemic due to wide spread contagious throughout the world and there was no treatment option in early 2020. Development of vaccine was the best preventive measure in any viral disease, in the line Covaxin (BBV152) an Indigenous vaccine of India was developed by Bharat Biotech International Ltd in association with Indian Council of Medical Research (ICMR). The development of Covaxin (Whole-Virion Inactivated Vero Cell derived) and screened successfully in preclinical and clinical studies. In this short communication, the author has put forwarded the complete journey of Covaxin (BBV152) and how successfully it come across. Recently it was found to be neutralizing the different variants too. DCGI has given nod for conduct of Phase II/III trial for the age group of 2 to 18 years category in May 2021.
Lingadurai S. Journey of Whole Virion Inactivated SARS-CoV-2 Vaccine- Covaxin (BBV152) an Indigenous Vaccine of India. Ann Pharmacol Pharm. 2021;6(1):1200..